D
David W. Hogg
Researcher at University of Toronto
Publications - 121
Citations - 29207
David W. Hogg is an academic researcher from University of Toronto. The author has contributed to research in topics: Melanoma & Germline mutation. The author has an hindex of 34, co-authored 113 publications receiving 25771 citations. Previous affiliations of David W. Hogg include University Health Network & Princess Margaret Cancer Centre.
Papers
More filters
Journal ArticleDOI
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).
Mark Harland,Alisa M. Goldstein,Kairen Kukalizch,Claire Taylor,David W. Hogg,Susana Puig,Celia Badenas,Nelleke A. Gruis,Jeanet A.C. ter Huurne,Wilma Bergman,Nicholas K. Hayward,Mitchell S. Stark,Hensin Tsao,Margaret A. Tucker,M. T. Landi,Giovanna Bianchi Scarrà,Paola Ghiorzo,Peter A. Kanetsky,David E. Elder,Graham J. Mann,Elizabeth A. Holland,D. Timothy Bishop,Julia A. Newton Bishop +22 more
TL;DR: The relatively low rate of CDKN2A mutation detection is not due to failure to detect mutations and implies the existence of other high penetrance melanoma susceptibility genes.
Journal ArticleDOI
Painted turtle cortex is resistant to an in vitro mimic of the ischemic mammalian penumbra.
Matthew E. Pamenter,David W. Hogg,Xiang Qun Gu,Leslie T. Buck,Gabriel G. Haddad,Gabriel G. Haddad +5 more
TL;DR: It is concluded that anoxia-tolerant turtle neurons are tolerant of exposure to a mammalian ischemic penumbral mimic solution and suggested that inhibitory GABAergic mechanisms also suppress electrical activity in isChemic cortex.
Posted Content
Fast Direct Methods for Gaussian Processes and the Analysis of NASA Kepler Mission Data
TL;DR: In this paper, the authors show that for the most commonly used covariance functions, the matrix $C$ can be hierarchically factored into a product of block low-rank updates of the identity matrix, yielding an $\mathcal O (n\log^2 n) $ algorithm for inversion.
Journal ArticleDOI
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.
Paul B. Chapman,Axel Hauschild,C. Robert,James Larkin,J.B.A.G. Haanen,A. Ribas,David W. Hogg,Steven J. O'Day,Paolo A. Ascierto,Alessandro Testori,Paul Lorigan,R. Dummer,J. A. Sosman,Claus Garbe,Rebecca Lee,K. B. Nolop,B. Nelson,Jeannie Hou,Keith T. Flaherty,Grant A. McArthur +19 more
TL;DR: A phase III trial to determine if vemurafenib improved overall survival (OS) and progression-free survival (PFS) in melanoma pts with V600EBRAF mutation.
Journal ArticleDOI
Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
Joni L. Rutter,Christina M. Bromley,Alisa M. Goldstein,David E. Elder,Elizabeth A. Holly,DuPont Guerry,Patricia Hartge,Jeffery P. Struewing,David W. Hogg,David W. Hogg,Allan C. Halpern,Richard W. Sagebiel,Margaret A. Tucker +12 more
TL;DR: The authors assessed melanoma risk according to family history of melanoma and other melanoma‐associated malignancies and evaluated the familial heterogeneity of melanomas, pancreaticmalignancies, and gastrointestinal malignancy.